| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1119: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR or BR are suitable (MA partial review of TA663) |
|
Medicine details |
|
| Medicine name | venetoclax (Venclyxto®) and obinutuzumab (Gazyva®) |
| Formulation | Tablet |
| Reference number | 3063 & 7593 |
| Indication | Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable |
| Company | AbbVie Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/02/2020 |
| NICE guidance | |